Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

2019-nCoV Outbreak and Cardiovascular Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04255940
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 5, 2020
Sponsor:
Information provided by (Responsible Party):
Pan-Pan Hao, Qilu Hospital of Shandong University

Brief Summary:
Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

Condition or disease
Cardiovascular Death; Major Adverse Cardiovascular Events

Detailed Description:
This survey aims to assess whether the public anxiety from a novel coronavirus (2019-nCoV) outbreak increases cardiovascular disease risk in China. Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 12000 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China
Actual Study Start Date : January 20, 2020
Estimated Primary Completion Date : April 30, 2020
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Group/Cohort
After outbreak
Past 3 months
Last year



Primary Outcome Measures :
  1. Cardiovascular Death [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Major Adverse Cardiovascular Events [ Time Frame: 3 months ]
  2. Times From symptom onset to hospital arrival [ Time Frame: 3 months ]
  3. Anxiety [ Time Frame: 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients visiting emergency department.
Criteria

Inclusion Criteria:

  • Patients visiting emergency department.

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04255940


Contacts
Layout table for location contacts
Contact: Panpan Hao, MD 86-18560086593 panda.how@sdu.edu.cn

Locations
Layout table for location information
China, Shandong
Affiliated Hospital of Binzhou Medical Universty Recruiting
Binzhou, Shandong, China
Contact: Min Feng, MD, PhD         
Sub-Investigator: Min Feng, MD, PhD         
Heze Municipal Hospital Recruiting
Heze, Shandong, China
Contact: Lujing Meng, MD         
Sub-Investigator: Lujing Meng, MD         
Shandong University Qilu Hospital Recruiting
Jinan, Shandong, China, 250012
Contact: Panpan Hao, MD, PHD       panda.how@126.com   
Sub-Investigator: Yanping Liu, MD         
Jinan Central Hospital, Shandong University Recruiting
Jinan, Shandong, China, 250013
Contact: Bin Li, MD       qingquan0615@163.com   
Sub-Investigator: Peixin Hu, MD         
Principal Investigator: Bin Li, MD, PhD         
First Hospital Affiliated with Shandong First Medical University Recruiting
Jinan, Shandong, China, 250014
Contact: Zhongwen Zhang, MD, PHD    18553104425    zhangzhongwen521@126.com   
Shandong Provincial Hospital, Shandong University Recruiting
Jinan, Shandong, China, 250021
Contact: Xin Zhang, MD         
Sub-Investigator: Xin Zhang, MD         
The Second Hospital of Shandong University Recruiting
Jinan, Shandong, China
Contact: kun Wen, MD         
Principal Investigator: Kun Wen, MD         
Sub-Investigator: Xuexi Hao, MD         
Jining Hospital of Traditional Chinese Medicine Recruiting
Jining, Shandong, China
Contact: Zhengyan Qu, MD         
Sub-Investigator: Zhengyan Qu, MD         
Qihe People's Hospital Recruiting
Qihe, Shandong, China
Contact: Jianjun Lu, MD         
Sub-Investigator: Jianjun Lu, MD         
Affiliated Hospital of Qingdao University Medical College Recruiting
Qingdao, Shandong, China, 266003
Contact: Liang Shan, MD         
Sub-Investigator: Liang Shan, MD         
Weihai Municipal Hospital Recruiting
Weihai, Shandong, China
Contact: Lei Cao, MD         
Sub-Investigator: Lei Cao, MD         
Central Hospital of Zibo Recruiting
Zibo, Shandong, China
Contact: Bo Li, MD, PhD         
Sub-Investigator: Bo Li, MD, PhD         
Sponsors and Collaborators
Qilu Hospital of Shandong University
Layout table for additonal information
Responsible Party: Pan-Pan Hao, Dr., Qilu Hospital of Shandong University
ClinicalTrials.gov Identifier: NCT04255940    
Other Study ID Numbers: 2019nCoV-CVD
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases